NUS Researchers Introduce Novel Technique for Fluorinated Therapeutic Compounds
Researchers at the National University of Singapore (NUS) have developed a new catalytic process that transforms epoxides into fluorinated oxetanes.
These compounds, highly sought after in drug development, have remained challenging to synthesise. The breakthrough provides a new pathway to these valuable drug scaffolds, potentially contributing to advancements in pharmaceutical research.
The study was led by experts from the NUS Department of Chemistry and the NUS Department of Pharmacy and Pharmaceutical Sciences, in collaboration with a researcher from the University of Pittsburgh, USA.
Four-membered heterocycles, including oxetanes and β-lactones, are commonly found in natural products and pharmaceuticals. Introducing fluorine into organic molecules can enhance their properties, improving success rates in drug discovery.
Replacing a CH2 unit in oxetanes or a C=O group in β-lactones with CF2 creates α,α-difluoro-oxetanes.
These compounds combine the benefits of small-ring heterocycles and fluorine, making them promising candidates for pharmaceutical applications. However, their synthesis has proven difficult.
To highlight the practical benefits of their method, the researchers successfully synthesised fluorine-containing analogues of oxetane, β-lactone, and carbonyl pharmacophores. Computational models of these analogues further suggested their potential use in drug design.
This advancement could lead to new medicines for conditions that have been difficult to treat. Ongoing studies are now focused on evaluating the biological properties of these newly synthesised compounds and extending the methodology to other heterocyclic drug-like structures.
